医学
血液透析
多重耐药
拉米夫定
人类免疫缺陷病毒(HIV)
内科学
重症监护医学
抗药性
疾病
药理学
病毒学
病毒
微生物学
乙型肝炎病毒
生物
作者
F. Bigirimana,Sigi Van den Wijngaert,Christelle Fosso,Karolien Stoffels,Charlotte Martin,Evelyne Maillart,Philippe Clevenbergh
摘要
We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir looks promising in terms of safety and efficacy even in patients with end-stage renal disease awaiting renal transplant. Both drugs are first in class ARVs so that there is no cross resistance with previous drugs, maintaining their efficacy against MDR HIV.
科研通智能强力驱动
Strongly Powered by AbleSci AI